Literature DB >> 27435754

Predictive validity of a quality measure for intensive substance use disorder treatment.

Eric M Schmidt1,2, Shalini Gupta1, Thomas Bowe1, Laura S Ellerbe1, Tyler E Phelps1, John W Finney1, Steven M Asch1, Keith Humphreys1, Jodie Trafton1,3, Megan Vanneman1,2, Alex H S Harris1.   

Abstract

BACKGROUND: Measures of substance use disorder (SUD) treatment quality are essential tools for performance improvement. The Veterans Health Administration (VHA) developed a measure of access to and engagement in intensive outpatient programs (IOPs) for SUD. However, predictive validity, or associations between this measure and treatment outcomes, has not been examined.
METHODS: Data on veterans with SUD came from 3 samples: the Outcomes Monitoring Project (N = 5436), a national evaluation of VHA mental health services (N = 339,887), and patients receiving detoxification services (N = 23,572). Propensity score-weighted mixed-effects regressions modeled associations between receiving at least 1 week of IOP treatment and patient outcomes, controlling for facility-level performance and a random effect for facility.
RESULTS: Propensity score weighting reduced or eliminated observable baseline differences between patient groups. Patients who accessed IOPs versus those who did not reported significantly reduced alcohol- and drug-related symptom severity, with significantly fewer past-month days drinking alcohol (b = 1.83, P < .001) and fewer past-month days intoxicated (b = 1.55, P < .001). Patients who received IOP after detoxification services had higher 6-month utilization of SUD outpatient visits (b = 2.09, P < .001), more subsequent detoxification episodes (b = 0.25, P < .001), and lower odds of 2-year mortality (odds ratio [OR] = 0.68, 95% confidence interval [CI]: 0.61-0.75; P < .001).
CONCLUSIONS: Receiving at least 1 week of SUD treatment in an IOP was associated with higher follow-up utilization, improved health outcomes, and reduced mortality. These associations lend support to the predictive validity of VHA's IOP quality measure. Future research should focus on measure feasibility and validity outside of VHA, and whether predictive validity is maintained once this quality measure is tied to performance incentives.

Entities:  

Keywords:  Access to care; intensive outpatient programs; mortality; patient participation; quality indicators; substance-related disorders

Mesh:

Year:  2016        PMID: 27435754     DOI: 10.1080/08897077.2016.1212779

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  7 in total

1.  Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys.

Authors:  Meredith G Harris; Chrianna Bharat; Meyer D Glantz; Nancy A Sampson; Ali Al-Hamzawi; Jordi Alonso; Ronny Bruffaerts; José Miguel Caldas de Almeida; Alfredo H Cia; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Hristo Hinkov; Elie G Karam; Georges Karam; Sing Lee; Jean-Pierre Lépine; Daphna Levinson; Victor Makanjuola; John McGrath; Zeina Mneimneh; Fernando Navarro-Mateu; Marina Piazza; José Posada-Villa; Charlene Rapsey; Hisateru Tachimori; Margreet Ten Have; Yolanda Torres; Maria Carmen Viana; Somnath Chatterji; Alan M Zaslavsky; Ronald C Kessler; Louisa Degenhardt
Journal:  Addiction       Date:  2019-06-02       Impact factor: 6.526

2.  Measuring and improving the quality of mental health care: a global perspective.

Authors:  Amy M Kilbourne; Kathryn Beck; Brigitta Spaeth-Rublee; Parashar Ramanuj; Robert W O'Brien; Naomi Tomoyasu; Harold Alan Pincus
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

3.  Payer-Level Care Coordination and Re-admission to Acute Mental Health Care for Uninsured Individuals.

Authors:  Steven L Proctor; Brittney Gursky-Landa; Jacob T Kannarkat; Johnny Guimaraes; John W Newcomer
Journal:  J Behav Health Serv Res       Date:  2022-02-22       Impact factor: 1.475

4.  Medical Detoxification for Nonopioid Substances is Associated With Lower Likelihood of Subsequent Linkage to Substance Use Disorder Treatment.

Authors:  Laura MacKinnon; JinCheol Choi; Mary Clare Kennedy; Rupinder Brar; M-J Milloy; Kanna Hayashi; Maria Eugenia Socías
Journal:  J Addict Med       Date:  2022-03-01       Impact factor: 4.647

5.  Association Between Process-Based Quality Indicators and Mortality for Patients With Substance Use Disorders.

Authors:  Susan M Paddock; Kimberly A Hepner; Teresa Hudson; Songthip Ounpraseuth; Amy M Schrader; Greer Sullivan; Katherine E Watkins
Journal:  J Stud Alcohol Drugs       Date:  2017-05       Impact factor: 2.582

Review 6.  At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.

Authors:  Mark K Greenwald; Tabitha E H Moses; Timothy A Roehrs
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

7.  Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.

Authors:  Kimberly Johnson; Holly Hills; Jifeng Ma; C Hendricks Brown; Mark McGovern
Journal:  Am J Drug Alcohol Abuse       Date:  2020-10-15       Impact factor: 3.829

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.